This is a broad portfolio that includes all aspects of life sciences. Some of the representative areas are bioengineering (brain computer interface, chips to grow and monitor cellular activities, and bioprinting), vaccines and therapeutics (nanolipoprotein particles for the delivery of vaccines and drugs, carbon nanotubes for drug delivery, KRAS inhibitors, and anti-bacterial minerals), medical diagnostics (molecular diagnostics, point-of-care testing, imaging, and forensic), life science instrumentation (PCR instruments, rapid PCR, fluid partitioning, microfluidics, and biosensors), and methods for the extraction and purification of rare earth elements using lanmodulin and other natural/synthetic bacterial proteins.
Portfolio News and Multimedia
Harmful biological pathogens, such as viruses, bacteria, fungi, protozoa, and worms, continue to pose a threat to the Joint Force. To combat these natural challenges and better defend warfighters from bioterrorism and biowarfare, the DTRA's Chemical and Biological Technologies Department in its role as the JSTO for the Chemical and Biological Defense Program collaborated with researchers at LLNL to create and evaluate a nanolipoprotein (NLP)-based multipathogen vaccine platform...
In late 2017, LLNL licensed a biomedical technology called nanolipoprotein particles (NLPs), which can deliver vaccines and drugs inside the cells in the human body, to Ann Arbor, Michigan-based EVOQ Therapeutics. EVOQ Therapeutics has announced two major agreements with Gilead Sciences Inc. and Amgen Inc. to work on the preclinical development of novel medicines to combat autoimmune diseases.
Leaders from the National Nuclear Security Administration, Congressional representatives and local elected officials gathered at Lawrence Livermore National Laboratory to celebrate the expansion of the Livermore Valley Open Campus.